CA2322494A1 - Novel nucleoside analogs and uses in treating disease - Google Patents

Novel nucleoside analogs and uses in treating disease Download PDF

Info

Publication number
CA2322494A1
CA2322494A1 CA002322494A CA2322494A CA2322494A1 CA 2322494 A1 CA2322494 A1 CA 2322494A1 CA 002322494 A CA002322494 A CA 002322494A CA 2322494 A CA2322494 A CA 2322494A CA 2322494 A1 CA2322494 A1 CA 2322494A1
Authority
CA
Canada
Prior art keywords
compound
beta
oriented
fluoro
evaporated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002322494A
Other languages
English (en)
French (fr)
Inventor
Annette M. Gero
Alexander L. Weis
Kirupathevy Pulenthiran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Unisearch Ltd
Lipitek International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/038,647 external-priority patent/US5939402A/en
Application filed by Unisearch Ltd, Lipitek International Inc filed Critical Unisearch Ltd
Publication of CA2322494A1 publication Critical patent/CA2322494A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA002322494A 1998-03-11 1999-03-11 Novel nucleoside analogs and uses in treating disease Abandoned CA2322494A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US09/038,647 US5939402A (en) 1995-09-21 1998-03-11 Nucleoside analogs and uses against parasitic infection
US09/219,947 1998-12-23
US09/038,647 1998-12-23
US09/220,307 US6207649B1 (en) 1995-09-21 1998-12-23 Nucleoside analogs and uses in treating disease
US09/219,947 US6242428B1 (en) 1995-09-21 1998-12-23 Nucleoside analogs and uses in treating Plasmodium falciparum infection
US09/220,307 1998-12-23
PCT/US1999/005360 WO1999045935A1 (en) 1998-03-11 1999-03-11 Novel nucleoside analogs and uses in treating disease

Publications (1)

Publication Number Publication Date
CA2322494A1 true CA2322494A1 (en) 1999-09-16

Family

ID=27365434

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002322494A Abandoned CA2322494A1 (en) 1998-03-11 1999-03-11 Novel nucleoside analogs and uses in treating disease

Country Status (5)

Country Link
EP (1) EP1069903A1 (enExample)
JP (1) JP2002506036A (enExample)
AU (1) AU3080899A (enExample)
CA (1) CA2322494A1 (enExample)
WO (1) WO1999045935A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
AU2007216721B2 (en) * 1998-08-10 2011-05-19 Centre National De La Recherche Scientifique Beta-L-2'-Deoxy Nucleosides for the Treatment of Hepatitis B
ATE313550T1 (de) * 1998-08-10 2006-01-15 Idenix Cayman Ltd Beta-l-2'-deoxynukleoside für die behandlung von hepatitis b virus
AU2004201286B2 (en) * 1998-08-10 2007-06-21 Centre National De La Recherche Scientifique (Cnrs) Beta-L-2'-Deoxy Nucleosides for the Treatment of Hepatitis B
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
EP1352910A1 (en) * 2002-04-10 2003-10-15 Grünenthal GmbH New analogs of nitrobenzylthioinosine
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
NZ541651A (en) * 2003-02-03 2009-01-31 Cv Therapeutics Inc Partial and full agonists of A1 adenosine receptors
GB0400290D0 (en) * 2004-01-08 2004-02-11 Medivir Ab dUTPase inhibitors
CA2947939A1 (en) * 2014-05-28 2015-12-03 Idenix Pharmaceuticals Llc Nucleoside derivatives for the treatment of cancer
CN106459127A (zh) * 2014-05-28 2017-02-22 艾登尼克斯药业有限公司 用于治疗癌症的核苷衍生物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
US5672594A (en) * 1994-10-24 1997-09-30 Genencor International, Inc. L-erythrosyl nucleosides

Also Published As

Publication number Publication date
EP1069903A1 (en) 2001-01-24
WO1999045935A1 (en) 1999-09-16
JP2002506036A (ja) 2002-02-26
AU3080899A (en) 1999-09-27

Similar Documents

Publication Publication Date Title
US5939402A (en) Nucleoside analogs and uses against parasitic infection
DE69829760T3 (de) Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
CA1333390C (en) Fluorinated nucleosides and process for treating retrovirus infections therewith
US5457187A (en) Oligonucleotides containing 5-fluorouracil
DE60038495T2 (de) Oligonukleotid n3'-p5' thiophosphoramidate: ihre synthese und verwendung
DE69427705T2 (de) Bor-cluster enthaltende nukleoside und oligonukleoside
EP3529255A1 (en) Trinucleotide mrna cap analogs
EP1206574A2 (en) Guanidinium functionalized oligomers and methods
JPH09505306A (ja) 非ホスホネートヌクレオシド間結合と混合している不確定キラリティーのホスホネートヌクレオシド間結合を有する合成オリゴマー
Venkatesan et al. Novel phosphoramidite building blocks in synthesis and applications toward modified oligonucleotides
CA2322494A1 (en) Novel nucleoside analogs and uses in treating disease
Rios Morales et al. Diastereoselective Synthesis of cycloSaligenyl‐Nucleosyl‐Phosphotriesters
US5153180A (en) Fluorinated nucleosides and process for treating retrovirus infections therewith
US20120149888A1 (en) Synthesis of ara-2'-o-methyl-nucleosides, corresponding phosphoramidites and oligonucleotides incorporating novel modifications for biological application in therapeuctics, diagnostics, g- tetrad forming oligonucleotides and aptamers
EP2854813B1 (en) Pyrazolotriazolyl nucleoside analogues and oligonucleotides comprising them
Kisakürek Perspectives in nucleoside and nucleic acid chemistry
WO1992003127A1 (en) Compositions and methods for treating hiv infections

Legal Events

Date Code Title Description
FZDE Dead